Cargando…

EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom

Detalles Bibliográficos
Autores principales:	Kohli, M., Maschio, M., Lee, A., Carroll, S., Van de Velde, N., Drummond, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256477/ http://dx.doi.org/10.1016/j.jval.2023.03.630

Ejemplares similares

EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance
por: Maschio, M, et al.
Publicado: (2022)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom
por: Maschio, Michael, et al.
Publicado: (2022)

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Axillary lymphadenopathy following bivalent COVID-19 booster vaccination
por: Lane, Elizabeth G., et al.
Publicado: (2023)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022
por: Lu, Peng-jun, et al.
Publicado: (2023)

FCC-ee Pre-Booster Accelerators
por: Ogur, S, et al.
Publicado: (2017)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
por: Tan, Ngoc H., et al.
Publicado: (2022)

EE179 Key Drivers of the Economically Justifiable Price of the COVID-19 Vaccine in England
por: Aballea, S, et al.
Publicado: (2022)

EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States
por: Paret, K, et al.
Publicado: (2022)

EE564 Study on the Value Pricing of COVID-19 Vaccine in China Based on the Evidence of Cost-Effectiveness Analysis
por: Fu, Y., et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
por: Alcendor, Donald J., et al.
Publicado: (2023)

Status of the FCC-ee Top-Up Booster Synchrotron
por: Härer, Bastian, et al.
Publicado: (2018)

Study of collective effects in the CERN FCC-ee top-up booster
por: Quartullo, D., et al.
Publicado: (2020)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
por: Chatzilena, Anastasia, et al.
Publicado: (2023)

The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization
por: Kohli, Michele, et al.
Publicado: (2021)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom
por: Zeevat, F, et al.
Publicado: (2021)

Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination
por: Fitzpatrick, Meagan C., et al.
Publicado: (2023)

Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster
por: Jabagi, Marie-Joelle, et al.
Publicado: (2023)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023)

Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults — United States, November 1–December 10, 2022
por: Sinclair, Alyssa H., et al.
Publicado: (2023)

Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022
por: Rosenblum, Hannah G., et al.
Publicado: (2022)

Health Tract No. 329: Writing
Publicado: (1868)

Challenges and Status of the Rapid Cycling Top-Up Booster for FCC-ee
por: Härer, Bastian, et al.
Publicado: (2017)

Optics design and correction challenges for the high energy booster of FCC-ee
por: Chance, Antoine, et al.
Publicado: (2023)

Design Studies Towards the FCC-ee Booster Ring Injection and Extraction
por: Howling, Emily Rose
Publicado: (2022)

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021
por: Ireland, Georgina, et al.
Publicado: (2022)

2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies
por: Aleissa, Muneerah M, et al.
Publicado: (2023)

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9g7n9he8pgnveak1s42bp6c2me